India ALLER NIL 2% Sodium Cromoglycate 2 Exports: Contraction and Mixed Buyer Concentration
TradeMagellan quarterly briefing. The available indicators for India pharmaceutical product for human consumption, described as ALLER NIL 2% sodium cromoglycate 2, show a negative period-over-period growth rate and a buyer concentration picture that cannot be fully reconciled.
Market temperature
The period-over-period growth rate is -4.54%. On the available indicator, this is a contraction reading. The data does not provide the base volume, value, or seasonal detail, so the decline should be treated as a movement in the reported series rather than a confirmed demand or revenue collapse.
Buyer concentration: a mixed signal
The top-three buyer share is 68.42%. The supplied market concentration index is 0.00. These two figures cannot be reconciled: a top-three share of 68.42% implies visible buyer concentration, while a zero HHI would normally suggest negligible buyer concentration. Because the snapshot provides both, we do not classify the market as fragmented or oligopolistic. Taken alone, the zero HHI would not support an oligopolistic reading, but it cannot be used to claim fragmentation when the top-three buyer share is 68.42%.
For procurement and investment decisions, the practical takeaway is that a large part of reported buyer activity is concentrated in the top three buyers. This should be treated as a signal to examine contract allocation and sourcing access, not as proof of monopsony or formal market structure.
Supplier base and sourcing approach
The available records list 5,176 active suppliers. This is a broad supplier universe for initial screening, not evidence that all listed suppliers are equally capable or compliant. A wide sourcing exercise can map potential producers, but qualification should narrow the list based on quality, regulatory readiness, lead time, and capacity availability.
Given the concentration signal among buyers, procurement teams should also ask whether core suppliers have allocation commitments that may affect availability for new buyers. The data does not show contract terms, so this is a verification step, not a conclusion.
Data notes
This page was automatically generated from the available trade information. The indicators used are a period-over-period growth rate of -4.54%, an HHI of 0.00, a top-three buyer share of 68.42%, and 5,176 active suppliers. The HHI and top-three buyer share are not reconcilable, so no formal market structure classification is made. The growth figure is a period-over-period change and should not be interpreted as demand or revenue growth. The supplier count reflects active suppliers in the available records and is not a vetted capacity or compliance list.
